Susceptibility of Helicobacter pylori to antimicrobial agents: effect of sulglycotide.
H. pylori is regarded as a primary etiologic factor in gastric disease and the therapies now include a combination of antimicrobial agents with antiulcer drugs. Here, the effect of a new gastroprotective agent, sulglycotide, on the in vitro anti-H. pylori activity of metronidazole, erythromycin, tetracycline, and amoxycillin was assessed. The assays in the absence of sulglycotide gave MIC value 0.10mg/L for erythromycin, 0.12mg/L for amoxycillin, 0.15mg/L for tetracycline and 14mg/L for metronidazole, while sulglycotide alone gave MIC value of 20mg/L. The sulglycotide at its optimal dose (5mg/L) evoked a 4-fold enhancement in the MIC of amoxycillin, 5-fold in tetracycline, and 8.3-fold in erythromycin, while the MIC of metronidazole improved 3.5-fold at 10mg/L sulglycotide. The results point towards the advantage of combination therapy of sulglycotide and antibiotics for H. pylori eradication.
Piotrowski
J
J
Research Center, University of Medicine and Dentistry of New Jersey, Newark 07103-2400, USA.
Murty
V L
VL
Slomiany
A
A
Slomiany
B L
BL
D000658:Amoxicillin / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D016480:Helicobacter pylori / Q000187:drug effects*; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D012795:Sialoglycoproteins / Q000494:pharmacology*; D013752:Tetracycline / Q000494:pharmacology
D012795:Sialoglycoproteins; D008795:Metronidazole; C009354:sulglicotide; D004917:Erythromycin; D000658:Amoxicillin; D013752:Tetracycline